A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

ClinicalTrials.gov ID: NCT05205070

Public ClinicalTrials.gov record NCT05205070. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects With Alopecia Areata

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata

Study identification

NCT ID: NCT05205070
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: AnaptysBio, Inc.; Industry
Enrollment: 45 participants

Conditions and interventions

Conditions

Alopecia Areata

Interventions

Rosnilimab Biological
Placebo Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 21, 2021
Primary completion: Jan 18, 2023
Completion: Mar 18, 2023
Last update posted: May 9, 2022

2021 – 2023

United States locations

U.S. sites: 16
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
10-105	Birmingham	Alabama	35205	Recruiting
Site10-103	Encinitas	California	92024	Recruiting
Site 10-113	Northridge	California	91324	Recruiting
Site 10-115	Chicago	Illinois	60611	Recruiting
10-104	Indianapolis	Indiana	46250	Recruiting
Site 10-109	Plainfield	Indiana	46168	Recruiting
Site 10-116	Louisville	Kentucky	40241	Recruiting
Site 10-117	Clarkston	Michigan	48346	Recruiting
Site 10-111	New York	New York	10029	Recruiting
Site 10-101	Charlotte	North Carolina	28277	Recruiting
Site 10-102	Bexley	Ohio	43208	Recruiting
Site 10-106	Tulsa	Oklahoma	74136	Recruiting
10-107	Upper Saint Clair	Pennsylvania	15241	Recruiting
10-110	Houston	Texas	77056	Recruiting
Site 10-108	San Antonio	Texas	78229	Recruiting
Site 10-114	Kenosha	Wisconsin	53144	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05205070, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 9, 2022 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05205070 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →